Thomas Schnitzer, MD

Professor of Medicine 
Northwestern University
Internal Medicine/Rheumatology                                                                      
tjs@northwestern.edu
312-503-1500

Current Research

New therapeutic agents in the treatment of osteoporosis: clinical trials and outcomes.  Interventional trials evaluating the use of both currently marketed as well as experimental therapies are undertaken in post-menopausal women, men, patients exposed to steroids and in other specialized populations.

Recent Publications

Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME.  Alendronate improves bone density in elderly female long-term care facility residents: a randomized, double-blind, placebo-controlled trial. Ann Int Med 136:742-746, 2002.
 
Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ, Rizzoli R.  Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988-96, 2002.
 
Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group.  Meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 23:495-578, 2002.
 
Siris ES, Bilezikian JP, Rubin MR, Black DM, Bockman RS, Bone HG, Hochberg MC, McClung MR, Schnitzer TJ. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab. 88:3482-6, 2003.
 
Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A.  Weekly oral alendronic acid in male osteoporosis. Clinical Drug Investigation 24: 333-341, 2004.